Chemed Corporation (NYSE: CHE) reported Q2 EPS of $1.71, $0.12 better than the analyst estimate of $1.59. Revenue for the quarter came in at $382 million versus the consensus estimate of $373.61 million.

Chemed Corporation sees FY2015 EPS of $6.60-$6.75, versus the consensus of $6.64.

Full Guidance for 2015

Full-year 2015 revenue growth for VITAS, prior to Medicare Cap, is estimated to be in the range of 4% to 5%. Admissions in 2015 are estimated to increase 4% to 5% and full-year Adjusted EBITDA margin, prior to Medicare Cap, is estimated to be 14% to 15%. Medicare Cap billing limitations for calendar year 2015 are estimated to be $2.8 million.

Roto-Rooter is forecasted to achieve full-year 2015 revenue growth of 5% to 6%. This revenue estimate is based upon continued expansion in water restoration services coupled with increased job pricing of approximately 1%. Adjusted EBITDA margin for 2015 is estimated in the range of 19.5% to 20.0%.

Management estimates that full-year 2015 adjusted earnings per diluted share, which excludes non-cash expense for stock options, costs related to litigation, and other discrete items, will be in the range of $6.60 to $6.75. This compares to Chemed’s 2014 reported adjusted earnings per diluted share of $6.07.

For earnings history and earnings-related data on Chemed Corporation (CHE) click here.